IMFINZI (AstraZeneca Pharmaceuticals LP)


Welcome to the PulseAid listing for the IMFINZI drug offered from AstraZeneca Pharmaceuticals LP. This Programmed Death Ligand-1 Blocker [EPC],Programmed Death Ligand-1 Antagonists [MoA],Programmed Death Ligand-1-directed Antibody Interactions [MoA],Antibodies, Monoclonal [Chemical/Ingredient] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: AstraZeneca Pharmaceuticals LP
NON-PROPRIETARY NAME: Durvalumab
SUBSTANCE NAME: DURVALUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Programmed Death Ligand-1 Blocker [EPC],Programmed Death Ligand-1 Antagonists [MoA],Programmed Death Ligand-1-directed Antibody Interactions [MoA],Antibodies, Monoclonal [Chemical/Ingredient]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION, SOLUTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2017-05-01
END MARKETING DATE: 0000-00-00


IMFINZI HUMAN PRESCRIPTION DRUG Details:

Item DescriptionIMFINZI from AstraZeneca Pharmaceuticals LP
LABELER NAME: AstraZeneca Pharmaceuticals LP
DEA SCHEDULE:
ACTIVE STRENGTH: 120(mg/2.4mL)
START MARKETING DATE: 2017-05-01
END MARKETING DATE: 0000-00-00
PRODUCT ID: 0310-4500_8baba4ea-2855-42fa-9bd9-5a7548d4cec3
PRODUCT NDC: 0310-4500
APPLICATION NUMBER: BLA761069

Other DURVALUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
AstraZeneca Pharmaceuticals LPIMFINZI